Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study
Table 2
Treatment pathway of patients with newly identified IAT stage† HCC over the period 2015-2017.
Newly identified IAT stage† HCC population
Total 19,649 (100%)
Treatment pathway since the IAT stage† diagnosis
Best supportive care only
10,584 (53.9%)
Systemic treatment only
3,951 (20.1%)
TACE only
3,382 (17.2%)
TACE and systemic treatment
1,241 (6.3%)
TARE only
176 (0.9%)
TARE and systemic treatment
130 (0.7%)
TACE and TARE
97 (0.5%)
TACE and TARE and systemic treatment
88 (0.4%)
Systemic treatment received
Targeted systemic treatment
4,681
Sorafenib
4,658
Lenvatinib
5
Regorafenib
334
Cabozantinib
4
Other chemotherapies
1,267
Other chemotherapies without targeted systemic treatment
